CAMBRIDGE CLINICAL LABORATORIES

Urology Services

Cambridge Clinical Laboratories (CCL) provides healthcare professionals worldwide with the most advanced diagnostic testing services from our UKAS accredited facility in the heart of scientific development, Cambridge, UK. CCL offers a comprehensive range of the very latest tests available worldwide for the early detection of a range of cancer types.

Prostate cancer:

PROSTATE-SPECIFIC ANTIGEN (PSA) (TOTAL AND FREE) – STANDARD INITIAL SCREENING

A protein produced by 'normal', as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. Elevated PSA levels may be indicative of a prostate issue requiring further investigation. We can also supply standard urine tests to resolve PSA issues caused by UTI interference.

STOCKHOLM3 – ADVANCED SCREENING

A blood test which analyses five protein markers and over 100 genetic markers, along with clinical data, to accurately predict the risk of aggressive prostate cancer, providing an informative indication about whether a biopsy is needed. Stockholm3 has now been evaluated in trials with over 75,000 men, creating one of the largest prostate cancer diagnosis datasets. Used as an advanced screening tool in men aged 45-74, with or without symptoms, and PSA between 1.5-20. https://www.a3p.com/en/stockholm3/

SELECT MDX – ADVANCED SCREENING/EARLY INVESTIGATION

SelectMDx helps physicians determine if a patient is at high or low risk for prostate cancer and which men can safely avoid biopsy. A non-invasive urine test - SelectMDx measures the expression of two mRNA cancer-related biomarkers (HOXC6 and DLX1) plus PSA and clinical data. Urine is collected by a physician following DRE.

PROCLARIX – ADVANCED SCREENING / AFTER MRI

A simple protein-based blood test that can be done with the same sample as the PSA test to give a more accurate risk of aggressive prostate cancer where PSA is in the diagnostic "grey zone" of 2-10. The Proclarix Risk Score delivers clear and immediate diagnostic support for further treatment decisions. Used for advanced early detection in men with PSA between 2-10, or alongside MRI to triage for biopsy. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987145/

PROSTATYPE – AFTER DIAGNOSIS

Prostatype®'s unique system identifies the genetic fingerprint of cancer by measuring information from cancer stem cell genes. The gene expressions together with other clinical parameters such as PSA, Gleason and Tumour stage are entered into the Classification of Prostatic Malignancy Algorithm (CPMA) software that is linked to a unique patient data base. The software calculates the so-called P-score that provides a measure of how aggressive the cancer is (10-year PCa-specific mortality risk without treatment), which facilitates the choice of optimal treatment for the patient.

HEREDITARY PROSTATE CANCER MARKERS

Our hereditary cancer clinical service aims to identify individuals at a higher-than-population risk for prostate cancer. We offer a range of panels to study genes associated with the most common hereditary cancers. Post determination, high risk individuals can be advised to have regular testing. Full comprehensive set of genes include APC, ATM1, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK22 , EPCAM3 , HOXB13, MLH1, MSH2, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS24 , POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, VHL.

OTHER CANCER TYPES:

BLADDER EPICHECK

This urine test provides patients and clinicians with a simple objective urine test to detect early onset bladder cancer and re-occurring bladder tumours. For surveillance, it is designed to be used in alternation with cystoscopy, reducing the number of cystoscopies required.
https://www.nice.org.uk/advice/mib293/chapter/The-technology

THE CCL PROSTATE CANCER PATHWAY:

The Cambridge Clinical Laboratories urology suite of tests is only available in the UK, via Health Care Professionals and our online provider – Goodbody https://health.goodbodyclinic.com/product/proclarix-prostate-cancer-screening-test. The suite includes tests to support every stage of the patient's prostate cancer pathway, offering you the tools to make better informed decisions.